How do you determine the choice of therapy for platinum resistant ovarian cancer in healthy, good performance status patients?

Platinum-resistant epithelial ovarian cancer is generally defined as relapse less than 6 months following completion of primary or the last platinum-based chemotherapy regimen. Options for therapy include conventional, commercially available drugs or potential clinical trials. If prior genetic testi...

Whenever possible I will consider a clinical trial, but clinical trials are not available for many patients. When a clinical trial is not an option, treating chemotherapy resistant ovarian cancer allows one to practice the ‘art of medicine’. As clinical trials have suggested that no one agent is...

In a patient with good PS 0-1 who opts for aggressive treatment one could consider the modified (outpatient) Rotterdam protocol of weekly cisplatin and oral etoposide which can yield a median PFS of 6.5 months and OS of 8.5 months. Inpatient version is no more effective.

Morgan, RD et. al "An Outpat...